(NASDAQ: RGNX) Regenxbio's forecast annual revenue growth rate of 46.1% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.84%.
Regenxbio's revenue in 2024 is $89,044,000.On average, 5 Wall Street analysts forecast RGNX's revenue for 2024 to be $4,006,441,312, with the lowest RGNX revenue forecast at $3,355,834,465, and the highest RGNX revenue forecast at $4,294,875,037. On average, 5 Wall Street analysts forecast RGNX's revenue for 2025 to be $14,914,138,904, with the lowest RGNX revenue forecast at $12,850,028,880, and the highest RGNX revenue forecast at $19,897,775,489.
In 2026, RGNX is forecast to generate $9,692,677,938 in revenue, with the lowest revenue forecast at $5,228,973,290 and the highest revenue forecast at $14,980,168,283.